President and Chief Executive Officer
Dr. Pons has served as our President, Chief Executive Officer and a member of our board of directors since April 2015. He has also served as a Scientific Advisor at Lightstone Ventures, a venture capital fund, since January 2019 and as a Venture Partner at venBio Partners, a venture capital firm, since January 2017. Prior to joining us, Dr. Pons was with Pfizer, Inc., a biopharmaceutical company, where he served as Senior Vice President and a member of the Pfizer World Research and Development Team and Chief Technology Officer for Pfizer Biotherapeutics from September 2009 to February 2015. From October 2007 to February 2015, he served as Chief Scientific Officer at Rinat Neuroscience Corporation, a subsidiary of Pfizer. Dr. Pons holds a B.S. in Biochemistry and an M.S. in Biotechnology from Autonoma University of Barcelona and a Ph.D. in Molecular and Cell Biology from the Institute on Fundamental Biology, Barcelona (Autonomous University of Barcelona).
Chief Business Officer
Mr. Caffo was previously President and CEO of Presage Biosciences, an oncology company that developed the first intratumoral microdosing platform for evaluation of multiple oncology agents. While at Presage he led the company’s partnering strategy, resulting in over $30 million in upfront cash. Mr. Caffo’s 24-year industry career has been focused on cancer therapeutics, personalized medicine, and applications of genomic technology. Mr. Caffo also led drug in-licensing at Perlegen Sciences, a genomic medicine spin-off of Affymetrix. Prior to that, he worked at Applied Biosystems (now Life Technologies) and its sister company Celera (now Quest Diagnostics) for 11 years in a number of technical and business roles, including managing the company’s genomics service business. Mr. Caffo has a B.S. in Microbiology from Pennsylvania State University.
Chief Financial Officer
Mr. García most recently served as CFO of PDL BioPharma (Nasdaq: PDLI). He has over 23 years of experience as a CFO having raised over $1.5 billion for public and private biotech and companies including BioTime, Marina Biotech, Nanosys, Nuvelo, Novacept, IntraBiotics Pharmaceuticals and Dendreon. Mr. García has led multiple merger and acquisition transactions and managed various functions including finance, accounting, treasury, investor relations, corporate communications, IT and facilities. Prior to becoming a CFO, he was a senior finance executive with Amgen. Mr. García holds a B.A. in economics and sociology with honors from Stanford University and an MBA with an emphasis in finance and accounting from UCLA.
Vice President, Finance and Chief Accounting Officer
Mr. Pietzke has served as our Vice President, Finance and Chief Accounting Officer since March 2020. Prior to joining us, he served as Senior Vice President, Finance and Chief Accounting Officer at Tricida, Inc., a biotechnology company, from April 2018 to March 2020. From June 2015 to April 2018, Mr. Pietzke served as Vice President, Finance and Chief Accounting Officer at PDL BioPharma, Inc., a biotechnology company. From July 2013 to June 2015, he served as a Senior Manager with Ernst & Young LLP, a professional services firm. From September 2000 to June 2013, Mr. Pietzke was with PricewaterhouseCoopers LLP, a professional services firm, where he served most recently as a Senior Manager. He holds a Bachelor of Business Science in Accounting from the University of Applied Sciences in Offenburg, Germany and is a certified public accountant in California and New Mexico.
Chief Medical Officer
Dr. Randolph previously served as Franchise Clinical Lead for the IBRANCE® clinical program at Pfizer, Inc., leading the early and late clinical development of this asset with initial registrations in the U.S. and rest of world. Before joining Pfizer, Dr. Randolph served as ZOLINZA® Clinical Lead at Merck, Inc., responsible for design and implementation of its hematology clinical life cycle plan as well as Molecular Profiling Lead, creating clinical trial translational plans across several oncology early development programs. Dr. Randolph received her M.D. and Ph.D. in cellular and molecular biology from University of Michigan and completed her oncology fellowship training at Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center where she studied hematopoietic cell transplant engineering methods to improve the graft-versus-leukemia effect for transplant patients. Dr. Randolph received her A.B. in biochemistry from Harvard University.
Chief Scientific Officer
Dr. Wan previously served as Senior Director, Biotechnology Clinical Development at Rinat (Pfizer), where she was responsible for the early development and translational medicine strategy across various therapeutic areas. Prior to that, Dr. Wan held positions as Director, Translational and Molecular Medicine at Pfizer and Director, Clinical Translational Medicine at Wyeth. Before joining Wyeth, Dr. Wan was Project Lead and Senior Scientist at Renovis. Dr. Wan received her Ph.D. in molecular and cell biology from University of California, Berkeley and A.B. degree in biochemical sciences from Harvard University.
Vice President, Operations
Dr. Chang was on the founding management team as VP Project Management at Labrys Biologics, which was acquired by Teva Pharmaceuticals. Prior to Labrys, Dr. Chang held positions as VP Project Management and Team Leader for RANEXA® at CV Therapeutics up until its acquisition by Gilead. Before that time, Dr. Chang managed the development and registration of VIRACEPT® at Agouron Pharmaceuticals, which was subsequently acquired by Pfizer. Dr. Chang earned his Ph.D. in microbiology and immunology from the University of California, Los Angeles and B.S. with honors from the University of California, Los Angeles. He conducted his post-doctoral training at the University of California, San Francisco as a Leukemia Society of America Research Fellow.
Vice President, Protein Science
Dr. Sim joined ALX Oncology in 2015 and brings expertise in target validation, protein design and engineering, and drug screening and optimization. Dr. Sim previously worked at Chiron, which was acquired by Novartis in 2007, where she held positions of increasing scientific responsibility. In her past role, she led cross-functional teams to design and engineer novel protein therapeutics for oncology and infectious disease programs. She completed her Ph.D. in Molecular Biology and B.Sc. with honors in Microbiology, both from the National University of Singapore.
Vice President, Chemistry, Manufacturing, and Controls
Mr. Stern has worked in the biopharmaceutical industry for over 32 years in a variety of leadership roles encompassing operations, contracts, drug development, and plant management at Teva Pharmaceuticals, Labrys Biologics, and Genentech. Mr. Stern has worked extensively in both drug substance and drug product for commercial and development products, including high concentration products and devices. His work has been instrumental in advancing new therapies from research into the clinic and large-scale commercial manufacturing. Mr. Stern earned his B.S. degree in fermentation science from University of California, Davis and MBA from San Francisco State University.
Acting General Counsel
Dr. Warner previously held the positions of Assistant General Counsel and Legal Site Head for Pfizer’s Rinat subsidiary, and was lead counsel to Pfizer’s Medicinal Chemistry and Pharmaceutical Sciences divisions. In addition, Dr. Warner is a registered patent attorney and formerly was the head of Pfizer’s St. Louis patent department. He has been the lead attorney for numerous successful outlicensing projects including Pfizer’s spin-off of RaQualia Pharma (Japan), and he has more than 35 years of experience as an attorney and a researcher in the life sciences. He earned his Ph.D. in organic chemistry from Indiana University, J.D. from St. Louis University, and B.S. with honors in chemistry at Centenary College of Louisiana.